U.S. corporate bond update: Bristol-Myers announced a jumbo 9 part deal to fund its Celgene purchase. It could total about $21 B and includes a 1.5-year FRN, along with a 3-year FRN, as well as 2-, 3-, 5-, 7-, 10-, 20-, and 30-year maturities. The offering could sap some demand from the Treasury's auction today.
https://thefly.com/landingPageNews.php?id=2904783
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.